The magnetocaloric effects and lower critical solution temperature (LCST) were investigated in a magnetothermally-responsive nanocarrier for magnetothermal drug release under alternating magnetic field (AMF). The Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticles with low T c were dispersed in a polymeric matrix consisting of N-Isopropyl acrylamide (NIPAAm) and N-hydroxymethyl acrylamide (HMAAm). The magnetocaloric effects and LCST of the nanocarriers were characterized by using high-resolution electron transmission microscopy, thermogravimetric analyses, and vibrating sample magnetometer. The maximum self-heating temperature of 42.9 • C was achieved by optimizing the Mn 0.2 Zn 0.8 Fe 2 O 4 concentration in the polymer matrix. By adjusting the NIPAAm to HMAAm ratio, the LCST was controlled at an ideal level of 40.1 • C for efficient thermosensitive drug delivery. Magnetothermally responsive drug release of Doxorubicin, an anticancer drug, was significantly enhanced by application of an external AMF on the nanocarriers. The cytotoxicity experimental results in vitro show good biocompatibility and efficient therapeutic effects in cancer treatment.
Introduction
In tumor therapy, several stimuli-responsive nanocarriers have been developed with various triggering strategies based on environmental changes, such as enzymes, pH, light, and temperature [1] [2] [3] [4] . Among all stimuli-responsive drug deliveries, the thermosensitive nanocarrier has been known for its combined advantage of hyperthermia [5] . Hyperthermia was reported to enhance permeability of tumor vasculature, leading to high uptake of the nanocarriers in lesions [6] . Furthermore, it can also enhance chemotherapy by increased drug cytotoxicity [7] [8] [9] . However, the great challenge has been on the design of a unique nanostructure capable of both efficient hyperthermia treatment of tumors and targeted thermochemotherapy. The delivery nanosystem also needs to be biocompatible and clinically viable.
As a typical inverse thermosensitive polymer, poly (N-isopropylacrylamide) (PNIPAAm) has been utilized as a drug-loaded carrier. PNIPAAm exhibits a lower critical solution temperature (LCST) around 32 • C, which is close to body temperature [10] . For desirable thermosensitive drug delivery at the physiological temperature (37 • C), LCST should be slightly above it (∼40 • C). Therefore, a critical step in the nanocarrier design is to have the LCST of the system controlled in the range of 40 • C-45 • C. It has been found that the LCST of thermosensitive polymer can be varied by addition of appropriate hydrophilic monomers, such as N, N -dimethylacrylamide (DMAAm) or N-hydroxymethylacrylamide (HMAAm) [11, 12] . By adjusting the ratio of NIPAAm to hydrophilic monomers, the LCST of random copolymer can readily change from 40 • C to 45 • C.
In targeted drug release, both spatial-temporal targeting and temperature control have been great challenges. In traditional approaches, heating may be divided into bodily and regional heating in clinics [13] . The former can be achieved mainly by hot water baths or perfusion with heated blood, which lacks selectivity [13] . Ultrasound, near-infrared (NIR), and electromagnetism have been used for more energyfocused treatments [14] [15] [16] [17] . Among them, nanoparticlemediated NIR and electromagnetic hyperthermia have been studied extensively for the advantages of simultaneous imaging and hyperthermia [18, 19] . In phototherapy, the treatment is often disadvantaged by limitation of light penetration.
The magnetic nanoparticle (MNP) mediated hyperthermia has been demonstrated to exhibit clinical effectiveness and spatial-temporal accuracy under an alternating magnetic field (AMF) due to hysteresis loss and/or Néel relaxation [20, 21] . For magnetic hyperthermia treatment, the field can easily penetrate the human tissues without adverse effects. The uptake of the MNPs in lesions can be achieved by a strong permanent gradient magnetic field, known as magnetic drug targeting (MDT) [22, 23] . MNPs have also been widely employed as contrast agents for magnetic resonance imaging (MRI) [24] . Thus, MNPs can serve as ideal candidates for drug delivery, targeting, imaging, and hyperthermia therapy simultaneously.
The temperature control in AMF is critical in drug release by nanocarriers. In general, hyperthermia raises the tissue temperature between 40.0 • C and 44.0 • C in order to kill cancerous cells while preserving the normal cells [25, 26] . Recent in vivo studies have demonstrated that the thermal enhancement of cytotoxicity is maximized at temperatures between 40.5 • C and 43 • C for several chemotherapeutic agents [27] . Therefore, it is necessary to control the maximum self-heating temperature around 43 • C for the magnetothermally-responsive drug delivery system. As an intrinsic property of the magnetic materials, the Curie temperature (Curie point, T c ) can be utilized to regulate the magnetocaloric effect of the nanoparticles [28, 29] . However, the T c of most commercially available MNPs, such as Fe 3 O 4 with T c of 860 K, is much higher than the body temperature [30] . For a system to work in a clinically viable temperature range, magnetic materials with low T c values are preferred. Mn-Zn ferrite (Mn 1−x Zn x Fe 2 O 4 ) is one of the MNPs with high magnetic permeability and low core losses. It is also well known that the properties of these ferrite materials are strongly influenced by their compositions and microstructures. By substitution of nonmagnetic Zn 2+ ions [32] .
In this study, a magnetothermally-responsive nanocarrier is designed and developed as shown in figure 1. In this figure, the thermosensitive copolymers are composed of NIPAAm and HMAAm. The Mn-Zn ferrite nanoparticles are embedded in the polymeric matrix. For clinical viability and safety, the Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticle is employed as its low T c is close to body temperature. The thermosensitive copolymers, with LCST around 40 • C, are prepared by adjusting the NIPAAm to HMAAm ratio. The mass fraction of Mn-Zn ferrite nanoparticle is varied to control the maximum temperature for drug delivery under AMF. The maximum self-heating temperature and the LCST of the nanocarrier are controlled in an appropriate temperature range (40-44 • C). It is noted that the maximum self-heating temperature should be slightly higher than LCST in order to trigger thermosensitive drug release completely under AMF (see figure 1) . Furthermore, water-soluble anticancer drug doxorubicin (Dox) is loaded in the nanocarrier for investigation of the magnetothermally-responsive drug release mechanism. Cytotoxicity is also investigated for both magnetothermally-responsive nanocarriers and Doxnanocarriers.
Experimental details

Materials
Manganese chloride (MnCl 2 · 4H 2 O), zinc chloride (ZnCl 2 anhydrous), ferric chloride (FeCl 3 anhydrous), dimethyl sulfoxide (DMSO), Poly (N-vinylpyrrolidone) (PVP; weightaverage molecular weight 24,000), N, N -methylenebisacrylamide (MBAAm), N-hydroxymethylacrylamide-(HMAAm) and ammonium persulfate (APS) were purchased from Shanghai Chemical Reagent Co., LTD. N, Nisopropylacrylamide (NIPAAm) was purchased from TCI. Doxorubicin hydrochloride (Dox · HCl) was provided by XinHua Hospital (Shanghai, China). Dulbecco minimum essential medium (DMEM), fetal bovine serum (FBS), and 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were purchased from Invitrogen corporation (USA). HMAAm was further purified by recrystallization from chloroform twice before use. NIPAAm was purified by recrystallization from hexane and toluene. DMSO were dried over CaH 2 and distilled before use. Other reagents were commercially available and were used as received. The dispersion polymerization method was used to prepare the magnetothermally-responsive nanocarriers. The nanocarriers were synthesized with the Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticles. They were added in the monomer mixtures prior to polymerization. MBAAm was used as a crosslinking agent to prevent the dissolution of P(NIPAAm-co-HMAAm) in water.
Preparation of Mn
In order to adjust the thermosensitive property of the nanocarriers, the ratios of NIPAAm to HMAAm were set to be 5:1 (435 mg, 3.85 mmol/78 mg, 0.77 mmol), 7:1 (452 mg, 3.99 mmol/58 mg, 0.57 mmol), and 9:1 (469 mg, 4.14 mmol/47 mg, 0.46 mmol) with Mn 0.2 Zn 0.8 Fe 2 O 4 loading of 8% (50 mg). Typically, in a 100-ml one-neck round-bottom flask equipped with a magnetic stirring bar, MBAAm (60 mg, 0.4 mmol), 0.2 g PVP, 20 mg APS, and certain amount of NIPAAm/HMAAm with the ratios mentioned above were dissolved in 50 ml of distilled water. Five milliliters of Mn 0.2 Zn 0.8 Fe 2 O 4 ferrofluid (10 mg ml −1 ) were added. The mixture was then degassed by three freeze-thaw-pump cycles in a nitrogen atmosphere, and heated to 70 • C to start the polymerization. The reaction proceeded under stirring (400 rpm) for 8 h at 70 • C. After completion of polymerization, the carrier was separated magnetically and thoroughly washed with distilled water several times to remove unreacted monomer, nonmagnetic particles, and other impurities.
In order to adjust the magnetothermal property of the nanocarriers, nanoparticle loadings of 6% (37.5 mg), 8% (50 mg), and 10% (62.5 mg) of the gross weight of the monomer and cross-linker were selected with a NIPAAm to HMAAm ratio of 7:1. Similar nanocarriers with different Mn 0.2 Zn 0.8 Fe 2 O 4 loadings were prepared by the same process described above. Finally, these products were freeze-dried and stored under vacuum at 18 • C. 
Characterization of Mn
The high-resolution transmission electron microscopy (HRTEM).
HRTEM was conducted by JEOL JEM-2010F (Japan, 200 KV) to observe the morphology of the Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticles and nanocarriers. The Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticles were dispersed into deionized water by ultrasonic sound. A drop of the solution was placed on a copper grid and left to dry before transferring into the TEM sample chamber. In order to observe the polymer in the nanocarriers, the specimen was prepared by drying a drop of nanocarrier solution on a copper grid coated with amorphous carbon. A small drop of phosphotungstic acid (PTA) solution (2 wt% in deionized water) was deposited onto the copper grid. After drying, the morphology of the nanocarriers was observed by TEM.
Fourier transform infrared (FT-IR) spectrometry.
Fourier transform infrared (FT-IR) spectrometry (Bruker Equinox55 FT-IR spectrometer, Germany) was employed to study the formation of the nanocarriers. The specimens were pressed into potassium bromide pellets.
Dynamic laser scattering (DLS).
The thermosensitive properties of the nanocarriers with different NIPAAm to HMAAm ratios were characterized by dynamic laser scattering (DLS). DLS measurements were made using a Malvern Autosizer 4700 (UK). The dried specimen was dispersed in deionized water (0.2 mg ml −1 ), sonicated and analyzed for the size distribution. The thermosensitive properties of the nanocarriers with different NIPAAm to HMAAm ratios were determined by measuring the nanoparticle sizes at different temperatures. The specimens were allowed to equilibrate for 1 min at set temperatures before measurement. 
Thermogravimetric analyses (TGA).
Magnetothermal property.
The heat generation of Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticles and the nanocarriers was achieved by using an AC magnetic field generator (Nanjing University Instrument Plant WG). The concentration of the suspensions in deionized water was adjusted to 5 mg ml −1 and the volume of each specimen was 5 ml. The conditions of the alternating magnetic field irradiation were fixed at 360 kHz and 6.5 kA m −1 .
Preparation and in vitro cytotoxicity of Dox-nanocarriers
The Dox-nanocarriers was prepared following a previously published protocol [34] . Typically, 5 mg Dox-HCl and 45 mg of nanocarriers with Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticle loadings of 8% and NIPAAm/HMAAm ratios of 7/1, were completely dissolved in 20 ml deionized water by ultrasonication for 10 min. The brown glass vial was sealed and shaken overnight at 25 • C to facilitate Dox uptake in the swelling shell of the nanocarrier. After loading, the Dox-nanocarrier was magnetically separated and freeze-dried. The whole procedure was performed in the dark.
The Drug loading content (DLC) was calculated according to the following formula [35] : To investigate the DLC of the drug-loaded carriers, Dox content in the supernatant and freeze-dried Dox-nanocarrier was determined by a UV/Vis spectrophotometer (Hitachi U-3310, Japan) and compared with the standard absorption curve of Dox in deionized water at 480 nm.
Drug release behavior of the Dox-nanocarriers in an external AMF.
The effect of AMF on drug release of the Dox-nanocarrier was investigated. The thermosensitiverelated drug release behaviors were studied at different temperatures (43 • C and 37 • C) as control.
Briefly, dried Dox-nanocarriers were dispersed ultrasonically in PBS (pH = 7.4) at a concentration of 5 mg ml −1 . Without AMF, 2 ml Dox-nanocarrier solution was dialyzed against 40 ml PBS at different temperatures (43 • C and 37 • C) for 24 h (MWCO: 3500, Shanghai Chemical Reagent Co., China). At predetermined time intervals, 4 ml media was extracted from a dialysis bag outside and replaced with fresh PBS. Dox content in the extracted solution was measured by UV/Vis spectrophotometry and the cumulative Dox release was calculated.
The magnetothermal drug release was performed with a similar procedure as for thermosensitive-related drug release behaviors described above with an external AMF. Briefly, 20 ml Dox-nanocarrier solution (5 mg ml −1 ) was placed in a double wall vacuum bottle, which was irradiated by an intermediate frequency alternating magnetic field generator at 360 kHz and 6.5 kA m −1 . At predetermined time intervals, as described above on thermosensitive-related drug release at a fixed temperature, 0.5 ml Dox-nanocarrier solution was extracted and dialyzed against 10 ml PBS for 30 min at 20 • C. The Dox content of the extracted solution was measured by UV/Vis spectrophotometry.
2.6.3. Cytotoxicity of nanocarriers and anti-tumor activity of Dox-nanocarriers in vitro.
In vitro cytotoxicity was evaluated by MTT assay. QBC cells (a human cholangiocarcinoma cell) were placed onto 96-well plates at 2.0 × 10 3 cell density and incubated with DMEM (containing 10% FBS) for 24 h. The cells were then exposed to DMEM with serial concentrations of the Dox-nanocarrier and pure nanocarrier. At the same time, the cells were subjected to DMEM with free Dox (5 µg ml −1 ) and without being selected as positive and negative control. After 48 h, the cells were washed with PBS and incubated with DMEM again for another 6 h. Then, the cell mediums were replaced with DMEM containing MTT (5 mg ml −1 ) for another 4 h and replaced again with DMSO. The optical densities (OD) were read at 490 nm using microtiter plate reader (BIO-RAD, USA).
The cell viability was calculated by the following equation:
Cell viability = (OD value of a specimen/OD value of the negative control) × 100%.
The average IC 50 (50% cell viability concentration) of the Dox-nanocarrier was estimated based on the MTT results. The MTT test was carried out in three replicates and each time five wells of cells were used for each specimen.
The influence of the Dox-nanocarrier and plain nanocarrier on apoptotic was reflected directly by Hoechst 33 258 staining assay. Briefly, after incubating with the Dox-nanocarriers (100 µg ml −1 ) and pure nanocarriers (400 µg ml −1 ) for 48 h, the cells were washed with PBS twice, then incubated with Hoechst 33 258 (5 µg ml −1 ) at room temperature for 5 min. At the end of incubation, cells were rinsed three times with PBS. Finally, the treated cells were observed using a fluorescence microscope (Olympus IX 71, Japan). appear between 3000 and 2800 cm −1 in figure 6 (b), which respectively represent asymmetric and symmetric vibration modes of CH 2 and CH 3 . It is well known that CH 2 and CH 3 are the main compositions of the polymer, which did not exist in Mn-Zn ferrite nanoparticles. Also nonmagnetic pure polymer was completely removed by repeated magnetic separation. Therefore, the two peaks appearing between 3000 and 2800 cm −1 , highlighted by the red circle in figure 6 (b), imply the polymer had been grafted on the surface of the magnetic nanoparticles.
Results and discussion
3.2.3. TGA result of nanocarriers. Figure 7 shows the thermogravimetric analysis (TGA) data of the weight losses between 200 • C and 550 • C, which correlate to the polymer mass fractions in the nanocarriers. These losses: 77.1%, 72.9%, and 64.8%, as shown in figure 7 , are corresponding to the different Mn 0.2 Zn 0.8 Fe 2 O 4 loadings of 6%, 8% and 10%, respectively. A similar trend in MNP content variation was reported by Purushotham et al [36] . However, the Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticle ratios in the carrier were higher than those feed ratios. This is attributable to nucleation of nonmagnetic polymers taking place separately from the MNPs and removed during magnetic separation. figure 4(a) ).
Thermosensitivity of nanocarriers.
The thermosensitivity of the nanocarriers was investigated by DLS analyses, as shown in figure 8 . As a result of a phase transition in PNIPAAm, the thermosensitive nanocarrier experiences a sharp coil-globule phase transition in water, transforming from an expanded hydrophilic structure below LCST to a compact hydrophobic structure above it. Therefore, the shell of the nanocarrier is in a shrinkage state, leading to the reduction of the nanocarriers' hydrodynamic diameter in water at temperatures above LCST (see schematic illustration in figure 1 ) [37] . The behavior has been observed by DLS, reflecting the size change of the nanoparticles in deionized water. The LCST values of nanocarriers with HMAAm molar ratios of 9:1, 7:1, and 5:1 are estimated to be 36. applications, particularly in terms of biological safety and physiological tolerance without using a temperature probe and controller [38] . The controlled drug release of Dox-nanocarrier was studied in PBS (pH = 7.4) under different conditions. The magnetothermal drug release was examined in an external AMF with the fixed parameters. As control, different temperatures (37 • C and 43 • C) were used to simulate the drug release of thermosensitive nanocarriers in physiological conditions and hyperthermia, respectively.
The accumulative doxorubicin release (%) from the drug carrier under these conditions is presented in figure 9 . At 37 • C, the cumulative release of Dox in PBS reaches approximately 35% within 8 h without any further release until 24 h. At 43 • C, the cumulative release of Dox in PBS is approximately 86% within 4 h, and up to 97% at 12 h. When the Dox-nanocarrier is exposed to an external AMF, the cumulative release of Dox is similar to those at 43 • C, approximately 84.9% within 4 h and 95% at 12 h.
Comparing these three curves in figure 9 , it can be seen that the drug accumulative release and initial release rates are much higher for the AFM-enhanced case and that at 43 • C. Since LCST (40.1 • C) of the thermosensitive nanocarriers is higher than 37 • C, the Dox release is mainly dependent on diffusion into the release media (PBS) at physiological temperature. However, in an external AMF, the magnetocaloric effect of the Mn-Zn ferrite core can induce heat generation, transferred through the polymer shell, causing a local temperature rise above its LCST. Consequently, the shell of nanocarrier collapses, resulting in rapid drug release. Similar results from controlling temperature have been reported in the literature [39] [40] [41] . However, thermosensitive drug release by the magnetocaloric effect is a unique approach and a more practical strategy compared to a simple water bath [42] [43] [44] . Moreover, the magnetocaloric effect can be controlled by selection of a Mn-Zn ferrite with proper T c and mass fraction of the Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticles. The effective control of drug release can also be achieved by an external AMF.
Stability of nanocarriers under different condition.
At the same time, the stabilities of the nanocarriers under different conditions were reflected in the drug release experiment. After the Dox-nanocarriers had been dispersed in PBS at 37 • C for 24 h, the solution was transparent without any precipitation. Meanwhile, when the Dox-nanocarriers had been dissolved in PBS at 43 • C after 24 h, the solution became a suspension without obvious precipitation. However, a distinct phenomenon has been observed that nanocarriers had become precipitations completely and arranged along with induction coils under AMF after 1 h. These phenomena showed the nanocarriers had good stability under physiological conditions and excellent magnetic targeting under AMF, which would benefit nanocarriers' application in clinics.
Biological properties of nanocarriers.
Cytotoxicities of nanocarriers and Dox-nanocarriers were assessed with free Dox (5 µg ml −1 ) as positive control and DMEM (containing 10% FBS) as negative control. The QBC cell viability after 48 h incubation with nanocarriers and Dox-nanocarriers at different concentrations, ranging from 0 to 400 µg ml −1 , were examined by the MTT method. As shown in figure 10 , the nanocarriers exhibit good biocompatibility with a cell viability more than 90% at the highest concentration of 400 µg ml −1 . In contrast, the Dox-nanocarriers show strong concentration-dependent cytotoxicity. As the Dox-nanocarrier concentration increases, the cell viability decreases significantly. At a Dox-nanocarrier concentration of 400 µg ml −1 , the corresponding cell viability is about 42.8%, which is similar to the result of free Dox (5 µg ml −1 , 43.9%, not shown). Although the cytotoxicity of Dox-nanocarriers is much lower than that of the free Dox, the actual content of Dox in nanocarriers (400 µg ml −1 ) is about 17 µg ml −1 . Dox-nanocarriers at a concentration of 400 µg ml −1 have been found to release free Dox of 5.9 µg ml −1 under the usual cell culture conditions at 37 • C. The effects of Dox-nanocarriers with different concentrations on QBC cell proliferation were also investigated by fluorescent imaging. Hoechst 33 258 was combined with the cell nuclei as molecular probes for its rapid uptake by living cells. Living cells incorporated with the Hoechst 33 258 dye exhibit blue fluorescence, whereas apoptotic cells and dead cells appear dark, as they are not stained (figure 11). After 24 h incubation with the Dox-nanocarriers (100 and 400 µg ml −1 ), cell proliferation is inhibited markedly and cell number decreases with the increase of Dox-nanocarrier concentration. Corresponding to the MTT result, cell proliferation is not affected by nanocarriers at a concentration of 400 µg ml −1 . As shown in figure 11 , the living cell number is close to that in the negative control. These results clearly indicate good biocompatibility and effective drug release of the nanocarriers.
Conclusions
Versatile nanocarriers for controlled drug release have been developed based on the magnetothermally triggered mechanism. The nanocarriers are designed to be capable of multifunctionalities in diagnosis and treatment, including cell targeting, imaging, magnetothermal drug release, and thermochemotherapy. A Mn 0.2 Zn 0.8 Fe 2 O 4 nanoparticle, with 
